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Abstract
The transcriptional regulation of peroxisome proliferator-activated receptor (PPAR) α by post-
translational modification, such as ubiquitin, has not been described. We report here for the first 
time an ubiquitin ligase (muscle ring finger-1/MuRF1) that inhibits fatty acid oxidation by 
inhibiting PPARα, but not PPARβ/δ or PPARγ in cardiomyocytes in vitro. Similarly, MuRF1 Tg+ 
hearts showed significant decreases in nuclear PPARα activity and acyl-carnitine intermediates, 
while MuRF1−/− hearts exhibited increased PPARα activity and acyl-carnitine intermediates. 
MuRF1 directly interacts with PPARα, mono-ubiquitinates it, and targets it for nuclear export to 
inhibit fatty acid oxidation in a proteasome independent manner. We then identified a previously 
undescribed nuclear export sequence in PPARα, along with three specific lysines (292, 310, 388) 
required for MuRF1s targeting of nuclear export. These studies identify the role of ubiquitination 
in regulating cardiac PPARα, including the ubiquitin ligase that may be responsible for this 
critical regulation of cardiac metabolism in heart failure.
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1. Introduction
Changes in cardiac metabolism occur in response to pathological hypertrophy, characterized 
by an upregulation of glucose uptake and glycolysis with either no change or a decrease in 
glucose oxidation (as recently reviewed Kolwicz et al., 2013). In parallel, decreases in fatty 
acid oxidation are seen with the downregulation of peroxisome proliferator-activated 
receptor (PPAR)α (Lehman and Kelly, 2002). A shift away from fatty acid oxidation to 
glucose use is considered beneficial because of the improved oxygen efficiency for ATP 
synthesis (Korvald et al., 2000; Burkhoff et al., 1991). In chronic ischemic cardiomyopathy, 
this becomes a critical point since oxygen is limited; however, these changes may also be 
maladaptive over time to sustain myocardial energetics and function (Kolwicz et al., 2013). 
In the present study, we describe a novel mechanism by which the ubiquitin ligase muscle 
ring finger-1 (MuRF1) inhibits myocardial fatty acid oxidation by removing PPARα from 
the nucleus in a novel and previously undescribed mechanism.
The PPAR family of transcription factors, including PPARα, PPARβ/δ, and PPARγ, 
regulate fatty acid utilization and oxidation in heart. Cardiomyocyte PPAR isoforms 
heterodimerize with the retinoid X receptor-α (RXRα), interact with multiple coactivators 
and repressors, to regulate the gene expression of proteins involved in lipid metabolism and 
energy regulation (Dowell et al., 1999; Kota et al., 2005; Michalik et al., 2006). Decreased 
cardiac PPAR activity has been implicated in the regulation of fatty acid utilization in 
mouse, rat, and dog models of heart failure (Pellieux et al., 2006; Morgan et al., 2006a,b; 
Barger et al., 2000; Barger and Kelly, 2000). However, the mechanisms by which PPAR is 
regulated itself in the context of heart failure has not been elucidated. Recent studies have 
provocatively suggested that post-translational modifications can be found on all three 
PPAR isoforms. For example, polyubiquitination of PPARβ/δ and PPARγ1/2 in cancer and 
adipo-cytes cells, respectively, has been identified, but the effects of polyubiquitination on 
the activity of these PPAR isoforms and whether degradation occurs are not known (Gareau 
and Lima, 2010; Gopinathan et al., 2009; Wadosky and Willis, 2012). These studies suggest 
that ubiquitin ligases, proteins that direct specific ubiquitination of substrates (PPARs in this 
case), may be regulating PPAR activity in some yet to be determined manner.
Muscle-specific ubiquitin ligase MuRF1 expression increases in chronic heart failure 
(Adams et al., 2007), left ventricular assist device (LVAD) placement in humans (Willis et 
al., 2009a,b), nutrient deprivation (Baskin and Taegtmeyer, 2011), and ischemic/ dilated 
human cardiomyopathy (Paul et al., 2004). It was originally identified as a transiently 
increasing protein in skeletal muscle atrophy (Bodine et al., 2001), mediating cardiac (and 
skeletal muscle) atrophy in response to glucocorticoids and unloading (Willis et al., 2009; 
Baehr et al., 2011). MuRF1 regulates cardiomyocyte mass by post-translationally modifying 
and regulating transcription factors in a disease-specific manner. In pathological cardiac 
hypertrophy, for example, MuRF1 inhibits cardiomyocyte growth by inhibiting PKC activity 
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(Arya et al., 2004) and interacting with and inhibiting the transcription factor serum 
response factor (SRF) activity (Willis et al., 2007). In cardiac ischemia-reperfusion injury, 
MuRF1 inhibits apoptosis by halting JNK-induced signaling – specifically, MuRF1 
polyubiquitinates phosphorylated c-Jun, targeting it for proteasome-dependent degradation, 
thereby effectively inhibiting downstream AP-1 (c-Jun/Fos) signaling (Li et al., 2011; 
Wadosky et al., 2014). MuRF1's ability to regulate cell signaling specifically in 
cardiomyocytes parallels its role in protein quality control and the turnover of key metabolic 
enzymes, including creatine kinase (Willis et al., 2009a,b). With MuRF1's prominence in 
interacting with metabolic enzymes regulating energy metabolism (e.g. creatine kinase, 
pyruvate kinase, 3-hydroxybutyrate dehydrogenase) and our recent identification of PPAR-
associated gene expression signatures in microarray analyses (e.g. gene ontology (GO) 
categories PPAR-γ coactivator (PGC), tricarboxylic acid (TCA) cycle, energy from 
oxidation) (Willis et al., 2009a,b), we investigated MuRF1 as a potential ubiquitin ligase that 
regulates cardiomyocyte PPAR activity.
In the present study, we expand on MuRF1's role in cardiac remodeling and cardioprotection 
by demonstrating that MuRF1 post-translationally regulates PPARα-mediated fatty acid 
oxidation. We describe for the first time a novel mechanism whereby MuRF1 specifically 
inhibits PPARα, but not PPARβ/δ or PPARγ activity, by targeting PPARα for nuclear 
export through non-canonical ubiq-uitination (monoubiquitination). Specifically, we 
demonstrate that MuRF1 interacts with and monoubiquitinates PPARα and targets nuclear 
export of PPARα through its ubiquitin ligase activity. Since ubiquitination occurs on 
lysines, the specific three lysines involved in ubiquitination were identified (K292, K310, 
and K358) to surround a nuclear export signal within PPARα that we identified and 
validated in the study. Together, these results identify that MuRF1 directs nuclear PPARα 
removal without being degraded by a nuclear export-dependent mechanism, driven by 
monoubiquitination. These studies identify that cardiomyocyte MuRF1 inhibits PPARα 
activity by a novel mechanism by which the cardiomyocyte nuclear receptor PPARα is 
monoubiquitinated and subsequently removed from the nucleus by the cells nuclear export 
machinery.
2. Materials and methods
Detailed methodology for the following techniques are provided in the Online Supplement: 
COS7, H9C2, HEK293T, HL-1 cell culturing; FLAG-PPARα mutant construct generation; 
qPCR; in vivo and in vitro ubiquitination assays; immunoprecipitation and Western blot 
analysis; luciferase activity reporter assays; MuRF1 Tg+ and MuRF1−/− mice generation; 
glucose and fatty acid oxidation assays; nuclear isolation; PPARα, PPARβ, and PPARγ 
activity assays; acylcarnitine quantification; fatty acid 123I-β-methyl-p-
iodophenylpentadecanoic acid (123I-BMIPP) and glucose analogs 18F-2-fluoro-2-deoxy-D-
glucose (18F-2-FDG) by single-photon emission computed tomography (SPECT) and 
computed tomography/positron emission tomography (CT/PET) analysis. Data are 
expressed as mean ± SEM. A One-way ANOVA test was used to determine the source of 
variation. Differences between specific groups were determined using a multiple comparison 
post-test via the Holm-Sidak method using the all-pairwise procedure. When appropriate, a 
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Student's t-test was performed to express differences between groups within one variable. 
Significance was defined as p < 0.05.
3. Results
Increasing MuRF1 expression alters cardiomyocyte glucose and fatty acid oxidation. Recent 
studies have illustrated that car-diomyocyte MuRF1 expression is critical to the cardiac 
hypertrophic response to pressure overload and the susceptibility to heart failure (Willis et 
al., 2009a,b, 2007). Like other ubiquitin ligases, MuRF1 interacts with multiple protein 
substrates, including those directly involved in the cardiac hypertrophic response (e.g. the 
transcription factor SRF) and in metabolic responses (e.g. creatine kinase) (Willis et al., 
2009a,b; Zhao et al., 2008). Since tran-scriptomic analysis has also provided support for 
MuRF1's role in energy metabolism (Willis et al., 2009a,b), we tested the hypothesis that 
MuRF1 regulates fatty acid and glucose oxidation at the level of the cardiomyocyte in the 
heart. To test this hypothesis, we increased MuRF1 expression using adenovirus constructs 
in neonatal rat cardiomyocytes (NRCMs) and measured the 14C-labeled CO2 released when 
cells were allowed to metabolize 14C-labeled glucose or 14C-labeled oleate (Fig. 1). 
Increasing MuRF1 expression using adenoviral vectors (25 MOI (multiplicity of infection)) 
resulted in a 62% increase in glucose oxidation and a 58% decrease in fatty acid oxidation in 
NRCMs (Fig. 1A and B, respectively). While the addition of the adenovirus to the NRCMs 
did not affect fatty acid oxidation (Fig. 1B, Untreated vs. 5–15 MOI Ad.GFP), it did 
enhance glucose oxidation (Fig. 1A, untreated vs. all other groups). Similarly, increasing 
MuRF1 in the HL-1 cardiomyocyte cell line resulted in enhanced glucose oxidation and 
decreased fatty acid oxidation (Fig. A.1A and B). Conversely, MuRF1 knock-down using 
siRNA in HL-1 cells resulted in decreased glucose oxidation and enhanced fatty acid 
(oleate) oxidation (Fig. A.1C and D), suggesting a role for endogenous MuRF1 in regulating 
fatty acid and glucose oxidation in cardiomyocytes. With increasing MuRF1 expression, 
fatty acid oxidation is inhibited while parallel increases in glucose oxidation result in an 
apparent shift of substrate utilization. Based on the amount of fatty acid and glucose 
oxidation measured, the amount of ATP resulting from the reduced fatty acid oxidation 
(129/mol) is compensated for by increases in ATP created by the measured enhanced 
glucose oxidation (38/mol) (Fig. 1C). Since these changes were reminiscent of those seen in 
heart failure driven by PPAR isoforms (van Bilsen et al., 2004; Madrazo and Kelly, 2008), 
we investigated the possibility that MuRF1 regulates this substrate shift by regulating PPAR 
activity.
MuRF1 specifically inhibits PPARα, but not PPARβ/δ or PPARγ transcriptional activity. 
The PPAR family of nuclear transcription factors contains three isoforms expressed in the 
heart: PPARα, PPARβ/δ, and PPARγ (Madrazo and Kelly, 2008). These nuclear receptors 
dimerize with RXRα, and bind to several co-regulators to interact with the PPAR response-
element in the promoters of genes regulated by PPAR family members (Madrazo and Kelly, 
2008). These genes encode for proteins that enhance fatty acid oxidation; at the same time, 
they encode for the glucose inhibitor pyruvate dehydrogenase kinase 4 (PDK4), which 
enhances its inhibition of glucose oxidation (Kolwicz et al., 2013; Doenst et al., 2013). In 
this way, inhibiting PPAR results in decreased fatty acid oxidation by transcriptionally 
down-regulating genes necessary for fatty acid oxidation, while simultaneous removing 
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PDK4. This would account for PPAR's divergent control of fatty acid and glucose oxidation 
(Kolwicz et al., 2013; Doenst et al., 2013). To delineate which of the three PPAR nuclear 
receptors MuRF1 may be inhibiting in car-diomyocytes, we next investigated if expression 
of MuRF1 affects PPAR transcriptional activity using luciferase reporter gene assays in 
COS-7 and H9C2 cells (Fig. 2). Since MuRF1 is found in both the nucleus and sarcomere 
(at the M-line bound to titin), assaying MuRF1's role in regulating PPARs in COS7 cells 
(without a sarco-mere) allowed us first to determine MuRF1's ability to regulate nuclear 
activity. Assaying MuRF1's regulation of PPARs in HL-1 cells then illustrated the relevance 
of these findings in a representative cardiomyocyte. In both COS7 and HL-1 cells, co-
transfection of a plasmid luciferase reporter driven by a PPAR-response element (PPRE) 
and a PPARα expression plasmid resulted in an enhanced PPAR activity; in contrast, co-
expression with a MuRF1 expression plasmid resulted in significant inhibition of PPARα 
(Fig. 2A and D). To determine the specificity of this response, we next investigated 
MuRF1's effect on PPARβ/δ and PPARγ gamma activity. MuRF1 failed to inhibit either 
PPARβ/δ or PPARγ induced PPRE-luciferase activity in COS7 or HL-1 cardiomyocyte-
derived cells (Fig. 2B,C,E,F).
We next established a method to quantify PPARα activity that could be applied to both in 
vitro and in vivo studies. MuRF1 expression was increased in HL-1 cells using adenovirus 
(Ad.MuRF1 and control Ad.GFP); parallel assays with MuRF1 knockdown using siRNA 
MuRF1 cocktail transfection (and a scramble control in parallel) were run. Nuclear protein 
was isolated and assayed for its ability to bind solid phase PPRE DNA bound, and this was 
quantified using a colorimetric anti-PPARα antibody. Increasing MuRF1 expression 
resulted in a dose-dependent decrease in PPARα activity (Fig. 2G). Decreasing MuRF1 
expression using siRNA enhanced PPARα expression over 2.5 fold of control levels (Fig. 
2H). In parallel studies, increasing, and decreasing MuRF1 altered PPARα-regulated gene 
expression (Fig. 2I and J). Taken together, these results suggest that MuRF1 specifically 
inhibits PPARα, the most abundant PPAR found in cardiomyocytes (Escher et al., 2001), in 
both non-cardiomyocyte and at least 2 cardiomyocyte-derived cell lines.
Cardiac MuRF1 expression regulates PPARα activity and fatty acid oxidation in vivo. With 
evidence that MuRF1 regulates PPARα, but not PPARβ/δ or PPARγ activity in multiple cell 
types, we next assayed MuRF1's regulation of these factors in vivo. Using previously 
described MuRF1 cardiac transgenic (Tg+) and MuRF1−/− mice (Willis et al., 2009a,b, 
2007), we assayed isolated cardiac nuclei for PPAR activity (described above in Fig. 2G). 
Nuclear extracts were placed on plates coated with PPRE DNA, followed by incubation with 
a capture antibody recognizing PPARα, PPARβ/δ, or PPARγ in separate assays (Fig. 3A). 
Consistent with our in vitro studies, increased α-MHC-driven cardiac MuRF1 expression in 
the MuRF1 Tg+ hearts resulted in a significant decrease in PPARα activity, approximately 
60% compared with wild-type controls. Conversely, MuRF1−/− hearts exhibited an 
approximately 5-fold increase in activity compared with wild-type controls (Fig. 3A). 
MuRF1 Tg+ and MuRF1−/− hearts had the same PPARβ/δ and PPARγ activities as their 
respective wild-type controls, indicating once again the specificity of MuRF1's effect on 
PPARα in vivo.
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Previous studies using transgenic mouse models have identified that increasing cardiac 
PPARα results in the increase import and oxidation of fatty acids (Madrazo and Kelly, 
2008). To determine the amount of imported and oxidized fatty acids, we performed an 
acylcarnitine profile analysis to quantify fatty acid oxidation intermediates, an assay 
established to reflect changes in PPARα activity in vivo (Makowski et al., 2009; Chen et al., 
2009; Laghezza et al., 2013; Turer et al., 2009) (Fig. 3C–F). Using this technique, we 
identified that compared to sibling control mice, MuRF1 Tg+ hearts demonstrated a 
significant decrease in total acylcarnitine levels (Fig. 3B). Conversely, MuRF1−/− hearts 
had a significant increase in total acylcarnitine (C2–C18 acyl-CoA species) levels compared 
with their sibling controls (Fig. 3B). When the total acylcarnitine was divided up into its 
component long, medium, and short chain acylcarnitines (Fig. 3C–F), similar significant 
differences were seen in the long and short chain acylcarnitines, reflecting their relative 
abundance compared with medium chain acylcarnitines. Additional in vivo studies 
investigating fatty acid and glucose uptake in the heart revealed no differences between 
MuRF1 Tg+, MuRF1−/−, and their respective wild-type sibling control hearts in studies 
using the fatty acid analog 123I-β-methyl-p-iodophenylpentadecanoic acid (123I-BMIPP) 
imaged by single-photon emission computed tomography (SPECT) and the glucose 
analog 18F-2-fluoro-2-deoxy-D-glucose (18F-2-FDG) imaged by computed tomography/
positron emission tomography (CT/PET) (Fig. A.2). These results illustrate that inhibition of 
fatty acid oxidation in MuRF1 Tg+ mice and enhanced fatty acid oxidation in MuRF1−/− 
mice, both revealed by significant differences in acyl-carnitine levels, cannot be explained 
by differences in fatty acid uptake and therefore must be due to regulators of fatty acid 
oxidation within the cell, such as PPARα.
We next assayed the expression levels of the PPARα-regulated genes acetyl-CoA 
carboxylase 1 (ACC1), aconitase 1 (ACO1), long chain acyl-CoA dehydrogenase (LCAD), 
and medium chain acyl-coenzyme A dehydrogensase (MCAD) by qPCR. Despite evidence 
that MuRF1 inhibits PPARα activity (Fig. 3A and B) and fatty acid oxidation (acyl-carnitine 
intermediates) (Fig. 3C–F) in vivo, transcription of PPARα-regulated genes (mRNA) were 
expressed in the opposite manner from expected. MuRF1 Tg+ hearts demonstrated a 
transcriptional upregulation of ACC1 and ACO1, whereas MuRF1−/− hearts expressed 
significantly less ACC1, ACO1, LCAD, and MCAD mRNA (Fig. 3G and H). Given the 
complexity of the PPARα complex and its multiple binding partners (RXR and other nuclear 
receptors), co-repressors, and co-stimulators, it is not surprising to see opposite activities 
invoked. For example, co-repression has been described when agonist-bound PPARs attract 
repressors and when PPAR homodimerization occurs (Fan et al., 2011; Flores et al., 2011; 
Borland et al., 2011). This sort of feedback mechanism common in physiology has only 
begun to be touched upon in PPAR biology and rarely in vivo.
MuRF1 does not affect the steady state protein levels of PPAR isoforms. Like most 
ubiquitin ligases reported to date, MuRF1 has largely been reported to polyubiquitinate and 
degrade its specific substrates, including troponin I, β-myosin heavy chain, cMyBP-c, and c-
Jun (Li et al., 2011; Kedar et al., 2004; Fielitz et al., 2007; Mearini et al., 2010). In these 
previous studies, increasing MuRF1 expression resulted in decreased substrate levels; 
conversely, reducing MuRF1 resulted in increased substrate protein levels. Since our results 
demonstrated that MuRF1 inhibits PPARα activity, we hypothesized that MuRF1 reduces 
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PPARα by targeting its degradation. To test this, we performed Western blot analysis on 
MuRF1 Tg+ and MuRF1−/− hearts to examine PPARα, PPARβ/δ, or PPARγ protein levels 
(Fig. 3G). Surprisingly, whereas MuRF1 clearly inhibited PPARα activity, it did not affect 
its steady state protein level in the heart. These findings led us to hypothesize that MuRF1 
inhibits PPARα activity in a manner independent of proteasome-mediated degradation.
MuRF1 interacts with PPARα to regulate its nuclear localization. We next determined if 
MuRF1 interacted with PPARα, given the possibility that MuRF1's regulation of PPARα 
could occur by indirect means since PPARα is only one component of a larger complex, 
including RXRα and PGC-1. Using HL-1 cells, we immunoprecipi-tated MuRF1 and were 
able to pull down and immunoblot endogenous PPARα (Fig. 4A). Similarly, when we 
immunoprecipitated endogenous PPARα we were able to pull down MuRF1 in HL-1 cells 
(Fig. 4B). To determine how this might occur, we next performed confocal microscopy 
analysis in HL-1 cells to examine the location of endogenous PPARα in the presence and 
absence of increased MuRF1 expression (Fig. 4C). As expected, endogenous PPARα 
expression was found throughout the cell in control cells, both in the cytosol and nucleus 
(Fig. 4C). Surprisingly, in cells with increased MuRF1 expression, endogenous PPARα was 
cleared from the nucleus (Fig. 4C). When larger a larger cell samplings were made, 
endogenous nuclear PPARα was present in 99.2% of control HL-1 cells (Fig. 4D). In 
contrast, increasing MuRF1 expression resulted in only 29.2% of the cells retaining 
endogenous nuclear PPARα (Fig. 4D). We hypothesized that MuRF1 may post-
translationally modify PPARα in such a way that it becomes excluded from the nucleus. 
This hypothesis is consistent with the fact that MuRF1 inhibits PPARα's (nuclear) activity 
without degrading protein substrate itself.
MuRF1 mediates PPARα nuclear export to inhibit its activity. Recent studies have identified 
that ubiquitination of nuclear proteins by ubiquitin ligases can target nuclear export in the 
context of cancer. For example, the ubiquitin ligase MDM2 mono-ubiquitinates p53, which 
results in nuclear export of p53 in cancer cells (Li et al., 2003; Carter et al., 2007). While 
this mechanism occurs in the context of cancer (e.g. in the H1299 human non-small cell lung 
carcinoma cell line and the U2OS osteosarcoma cell line), similar mechanisms have not 
been described in muscle cells. Therefore, we investigated if MuRF1's ability to remove 
nuclear PPARα in cardiomyocytes was related to nuclear export. We used the potent and 
specific nuclear export inhibitor leptomycin B (LMB) (Kudo et al., 1998). Leptomycin B 
alkylates and inhibits the CRM1/ exportin 1 (XPO1) protein required for the nuclear export 
of proteins containing a nuclear export signal (NES), by glycosylating a cysteine residue 
(Kudo et al., 1999). MuRF1's ability to remove endogenous nuclear PPARα was inhibited in 
the presence of LMB treatment, indicating a role for the NES machinery in this process. In 
the absence of LMB, increasing MuRF1 expression resulted in endogenous nuclear PPARα 
localization in 11.3% cells, compared with 82.3% in control cells, respectively (Fig. 5A, 
upper vs. lower rows). In parallel experiments using LMB, MuRF1's ability to alter the 
nuclear localization of PPARα was inhibited, with 95.7% of the nuclei having endogenous 
PPARα, compared with 96.4% in control cells (Fig. 5B, upper vs. lower rows). We next 
quantified how the nuclear transport effect of MuRF1 affected endogenous PPARα activity 
by assaying the amount of nuclear PPARα that could bind to a solid phase DNA with a 
PPRE. Compared to control cells, an 80% decrease in binding activity was found when 
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MuRF1 expression was increased (Fig. 5C). Consistent with our confocal analysis, we 
identified that LMB inhibited MuRF1's ability to decrease endogenous PPARα activity in 
cardiac-derived cells (Fig. 5D). Whereas MuRF1 is rarely found in the nucleus, LMB 
treatment “captured” MuRF1 in the nucleus of approximately 25% of the cells (Fig. 5D). It 
is possible that MuRF1's nuclear import and export is so swift under normal conditions that 
noticeable accumulation of MuRF1 in the nucleus is not seen, but can be uncovered in the 
presence of LMB. MuRF1's ability to enter and exit the nucleus (albeit briefly) would also 
explain MuRF1's inhibition of other nuclear substrate activity, including SRF shown 
previously (Willis et al., 2007), and PPARα in the current study. Taken together, these 
findings indicate MuRF1 enters and then rapidly moves out of the nucleus to remove 
endogenous PPARα in a manner dependent upon the cell's nuclear export machinery.
MuRF1 monoubiquitinates PPARα in vitro and in vivo. As a muscle-specific ubiquitin 
ligase, MuRF1's ability to regulate interacting substrates has been linked to its ability to 
ubiquitinate the protein at specific lysines. MuRF1 polyubiquitinates and degrades cTnI, c-
Jun, and β-MHC in a proteasome-dependent manner (Li et al., 2011; Kedar et al., 2004; 
Fielitz et al., 2007). In contrast, other substrates, such as PKC– and SRF, localization and 
activity are regulated without protein degradation (Arya et al., 2004; Willis et al., 2007). 
Since MuRF1 interacts with PPARα, inhibits its activity, but does not change the steady 
state protein levels when it is increased, we next detailed MuRF1's interaction and 
ubiquitination of PPARα. Using MuRF1 mapping constructs, we identified that MuRF1 
binds PPARα through its B-box and MuRF-family conserved (MFC) regions (Fig. 6A). We 
next performed an in vitro ubiquiti-nation assay where we added recombinant E1, E2 
(UbcH5c), MuRF1, PPARα, and ubiquitin. Western blot analysis of this reaction yielded 
both a predominant unmodified form halfway between the 52 and 76 kDa molecular weight 
markers (Fig. 6B). A single additional band was seen in the full reaction (far right lane), but 
not in the control reactions missing just 1 component (E1, E2, MuRF1, PPARα, OR 
ubiquitin, respectively). This specific band (i.e. not formed without all the reaction 
components present) was found between the PPARα (~54 kDa) and below the 76 kDa 
marker. Since a single ubiquitin has a molecular mass of 8.5 kDa, it represents a mono-
ubiquitination (estimated to be 62.5 kDa =54 kDa + 8.5 kDa). This is not the canonical poly-
ubiquitination of PPARα, since these post-translationally modified chains appear as a smear. 
For example, MuRF1 simultaneously autoubiquitinated itself by this type of poly-ubiquitin 
chain (Fig. 6B, lower anti-GST blot), revealing that the reaction stoichiometry drove MuRF1 
to monoubiquitinated PPARα in vitro. Prior studies have revealed MuRF1's ability to auto-
polyubiquitinate through all of the possible ubiquitin lysine chains (K6, K11, K27, K29, 
K33, K48, K63) (Kim et al., 2007), whereas mono- and multi-monoubiquitination patterns 
are not associated with ubiquitin chain formation (Sadowski et al., 2012).
Like many cell free phenomena, these in vitro ubiquitination results needed confirmation in 
the more complex milieu of the cell. Therefore, we next sought to confirm the relevance of 
MuRF1's apparent monoubiquitination of PPARα in the more complex milieu of a cell, with 
multiple other proteins present, including multiple E2s known to drive the complexity and 
type of MuRF1 ubiquitin chains (Kim et al., 2007). Interestingly, MuRF1 similarly 
monoubiquitinated PPARα in cells demonstrating that increasing MuRF1 expression results 
in increased post-translational modification of PPARα in both HL-1 cells and HEK293T 
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cells, which results in the addition of one or two ubiquitin modifications (di-mono-
ubiquitination) being added (Fig. 6C and D, respectively). Both mono- and di-
monoubiquitin modifications have been reported to mediate changes in cellular localization 
in various cancer cell lines (Haglund et al., 2003; Lee et al., 2008; Liu and Subramani, 
2013). These studies illustrate that increasing MuRF1 expression induces a multi-
monoubiquitination of PPARα, which may be responsible for the resulting nuclear export 
observed.
An interesting finding related to nuclear export machinery inhibited by LMB is that it is 
dependent upon recognition of nuclear export signals (NES). However, the sequences that 
make up the NES(s) for PPARα have not been described to date. Nuclear export signals are 
made up of hydrophobic residues, often leucines (L), arranged in a LXXXLXXLXL motif, 
where X is any other amino acid. Given the critical nature of the leucines in NESs, we first 
scanned the PPARα amino acid sequence for leucine clusters and found three near each 
other at amino acid residues 300–308 (Fig. A.3B and C). In addition to this leucine rich 
region (NES1), we next used an algorithm to identify any additional potential NES 
sequences in PPARα. Based on published analysis of a wide range of nuclear export signals, 
we used a bioinformatics approach to predict other potential leucine-rich nuclear export 
signals in PPARα (http://www.cbs.dtu.dk/services/NetNES/) (la Cour et al., 2004). This 
analysis identified a cluster of 3 predicted NES amino residues in an 8 amino acid cluster at 
residues 368–377 (lelddsdisl), suggesting a putative nuclear export sequence, which we 
named NES2 (Fig. A.3B and C). These sequences, identified as NES1 (ldlndqvtl) and NES2 
(leldds-disl), are located in the ligand-binding domain (domain E/F) in PPARα, detailed in 
Fig. A.3A. Using standard published procedures (Simon-Areces et al., 2013; Lin et al., 
2005; Durchschlag et al., 2004; Brown et al., 2004; Hake et al., 2000), we next examined 
whether these putative NES1 and NES2 regions were functional, by mutating the Leucine to 
Alanine in the NES1 and NES2 regions. If NES1 and/or NES2 were actual nuclear export 
sequences, these mutations would prevent their nuclear export and confirm their role in 
targeting PPARα for nuclear export in cardiomyocytes. HL-1 cells were transfected with 1) 
wild-type PPARα; 2) NES1 mutant PPARα; or 3) NES2 mutant PPARα in parallel (Fig. 
6A). Compared to wild-type PPARα (Fig. 7A, top panels), NES1 mutant PPARα 
demonstrated an increased nuclear localization in experiments run in parallel (Fig. 7A, 
middle panels). In contrast, the NES2 mutant PPARα did not have an altered nuclear 
localization compared with wild-type PPARα (Fig. 7A, bottom panels). These studies 
identify for the first time that the novel NES1 is a bone fide NES sequence in PPARα. 
Despite NES1's ability to maintain its nuclear localization, increased MuRF1 expression was 
able to specifically export both the NES1 and NES2 mutant PPARα (Fig. 7B and Fig. A.
3D).
MuRF1's PPARα monoubiquitination requires 3 lysine groups flanking the newly identified 
NES1. To determine which lysines in PPARα are monoubiquitinated, and to illustrate 
MuRF1's dependence upon this ubiquitination for nuclear export of PPARα, we created 
PPARα mutant proteins that lacked specific lysine groups (by mutations changing lysine to 
arginine) surrounding the 2 putative NES sites that we identified in the experiment described 
above (Fig. A.3A). Six PPARα mutants, named A1, A2, A3, A4, A5, and A6 were created, 
each with only 1 lysine altered. When cells were transfected with A1–A6 and MuRF1 
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expression was increased, we found that PPARα A1, PPARα A2, and PPARα A3 were not 
removed from the nucleus as was wild-type PPARα when MuRF1 expression was increased 
(Fig. 8). PPARα A4–A6 mutants were removed from the nucleus to the same extent as wild-
type PPARα (Fig. A.4) and parallel control cells (Fig. A.5). These studies illustrate the 
necessity of the three individual lysines surrounding the novel NES1 PPARα, which result 
in the mono- and/or di-mono-ubiquitination that we identified in cells and in vitro 
ubiquitination assays.
4. Discussion
In the present study, we identified the striated muscle-specific MuRF1 ubiquitin ligase as a 
direct regulator of PPARα activity in the heart in vivo. Increasing MuRF1 expression 
decreased PPARα activity while decreasing MuRF1 expression using shRNA or mouse 
models lacking cardiac MuRF1 resulted in significant increases in PPARα activity. 
MuRF1's inhibition of PPARα occurred using a mechanism requiring nuclear export, 
evidenced by its inhibition by leptomycin B. After identifying the first NES in PPARα using 
mutational analysis, we next demonstrated that MuRF1 is mono-ubiquitinated using in vitro 
ubiquitination assays. In cell models in vivo, we found that increasing MuRF1 
monoubiquitinated or di-monoubiquitinated PPARα. When lysines A1, A2, and A3 
surrounding the novel NES1 were mutated to arginine, MuRF1's ability to induce nuclear 
export was prevented. We proposed that increasing MuRF1 results in MuRF1's translocation 
to the nucleus where PPARα is monoubiquitinated and preferentially recognized by CRM1 
and the nuclear export complex, mediating its subsequent export and inhibition of activity 
(transcription of PPARα-regulated genes). These studies parallel recent findings in cancer, 
whereby the ubiquitin ligase MDM2 was found to monoubiquitinate p53 to target its nuclear 
export (Li et al., 2003). In contrast to MDM2 and p53, we have not found that increased 
MuRF1 levels poly-ubiquitinates and degrades PPARα like increased MDM2 levels have 
been reported. This novel pathway possibly regulates the newly identified NES1 sequence-
targeted nuclear export. These findings are also the first description of a pathway by which 
cardiac PPAR isoform levels are regulated and may be critical in the substrate switching the 
heart utilizes to adapt in cardiac diseases, such as cardiac hypertrophy and heart failure.
A recent study has identified that PPARγ is exported rapidly from the nucleus after being 
phosphorylated in cancer cell lines, including MCF-7 breast adenocarcinoma and HEK293T 
embryonic kidney cell lines (Burgermeister and Seger, 2007). This mitogen-induced nuclear 
export is through its direct interaction with the MAPK/ERK-kinases 1/2 (MEKs) 
(Burgermeister and Seger, 2007). Of particular interest in this study was that the NES that 
interacts with CRM1/exportin-1 was found in MEK1, not PPARγ. This suggests that 
MEK1's interaction with PPARγ was critical in its nuclear export and possibly otherwise 
independent of any phosphorylation of PPARγ itself. Recent studies have found that MEK1 
similarly directs PPARα, although with PPARα MEK1 interacts with the C-terminal end, 
where a proposed, but not confirmed LXXLL NES motif was hypothesized (el Azzouzi et 
al., 2012). These studies were particularly interesting as they were performed in the NKL-
Tag ventricular muscle cell line and MEK1 inhibitors in wild-type mice appeared to parallel 
these in vitro studies (el Azzouzi et al., 2012).
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The regulation of PPARα by post-translational modification with ubiquitin has been 
demonstrated in rat hepatoma and the HepG2 cell lines (Gopinathan et al., 2009). The E3 
MDM2 has been associated with increased poly-ubiquitination of PPARα; interestingly, the 
MDM2 to PPARα ratio determined if MDM2 activated (MDM2: PPARα <1) or inhibited 
(MDM2: PPARα >1) (Gopinathan et al., 2009). Parallel studies in another hepatoma cell 
line (HepG2) illustrated that MDM2's inhibition of PPARα activity was due to its 
degradation (Blanquart et al., 2002; Blanquart et al., 2004; Hirotani et al., 2001). Both sets 
of studies identified that MDM2-dependent modulation of PPARα activity was dependent 
upon the presence of the PPARα ligand Wy14643 (Gopinathan et al., 2009; Blanquart et al., 
2002, 2004; Hirotani et al., 2001). Interestingly, in the present study, we did not see MuRF1 
poly-ubiquitinate or degrade PPARα no matter how low or high the ratio of MuRF1:PPARα 
was (data not shown). Similarly, all experiments were performed in the presence of serum, 
which included endogenous PPARα ligands. We did not find the addition of Wy14643 
altered the results of our studies, so we did not include them after our initial evaluation.
Monoubiquitination, like that found on PPARα resulting from MuRF1 ubiquitination, has 
been associated with directing changes in sub-cellular location. Classically, this has been 
described at the plasma membrane and associated with endosomal targeting of receptors 
after ligand engagement. One example involves receptor tyrosine kinases (RTKs), where by 
interaction with their cognate ligand results in monoubiquitination at the plasma membrane 
(Haglund et al., 2003). Upon monoubiquitination, these RTKs move to the endosomal 
compartment to be shuttled to the lysosome, not recycled to the plasma membrane, in 
multiple cancer cells, including NIH 3T3 cells, B82L, and HeLa (Haglund et al., 2003). The 
ubiquitin ligase MDM2, with ubiquitin ligase, has been reported to ubiquitinate p53, with 
monoubiquitination of p53 being sufficient for nuclear export (Carter et al., 2007). 
Interestingly, MDM2 ubiq-uitination of p53 contributes to two different steps of p53's 
nuclear export: 1) ubiquitination exposes a carboxyl-terminal NES, and 2) promotes the 
disassociation of MDM2 (Carter et al., 2007). Further studies indicated that MDM2's 
monoubiquitination of p53 promotes the interaction of the SUMO E3 ligase PIASγ with 
p53, enhancing SUMOylation and nuclear export in U2OS osteosarcoma cells and MEF 
cells (Carter et al., 2007). Monoubiquitination of nuclear PTEN in cancer cells has 
demonstrated that the mono-ubiquitination of PTEN is essential for nuclear import (Trotman 
et al., 2007). In contrast to p53 and the present study, the post-translational modification of a 
nuclear protein targets the substrate to move into the nucleus, illustrating how nuclear 
localization signals (NLS) can me regulated by monoubiquitination in the same manner as 
NES's can.
The mismatch between MuRF1's effects on PPARα activity/ localization and on PPARα-
regulated gene expression was unexpected. But this may be the result of the multiple roles 
MuRF1 has in cardiomyocyte metabolism and the multiple levels that PPARα may be 
regulated. MuRF1 may be directly (or indirectly) affecting compensatory gene regulation at 
numerous levels, resulting in complex and possibly contradictory relationships. For 
example, MuRF1 regulates metabolism by regulating the turnover of creatine kinase (critical 
for ATP shuttling to the sarcomere) (Willis et al., 2009a,b), localizes in the mitochondria 
and reduces ROS production in vivo (Mattox et al., 2014). MuRF1 itself interacts (in Y2H 
systems) with numerous metabolic proteins, such as enoyl coenzyme A hydratase, malonyl-
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CoA decarboxylase, and multiple other proteins involved in glycolysis and the Krebs cycle 
(e.g. Aldolase A, Pyruvate kinase, Pyruvate dehydrogenase) (Willis et al., 2009a,b; Witt et 
al., 2005). Taken together, MuRF1's combined effects on metabolism, in addition to the 
regulation of PPARα described here, is complex. There, the unique findings on the overall 
metabolic responses here are not completely surprising. The transcriptional complex made 
up of PPARα and RXRα includes a myriad of other proteins, including co-repressors, some 
of which have been described to bind agonist-bound PPARs, some just recently described 
(Borland et al., 2011). Having these multiple players has made predicting the effects of 
reducing PPAR protein on PPAR transcription. The ratio of PPARα:RXRα in 
cardiomyocytes, for example, may be more important in determining PPAR activity than the 
levels of PPARα alone. Recent studies have shown that enhanced PPAR expression can 
change the ratio of PPAR:RXRα, favoring PPAR homodimers that can act as repressors 
(opposite of what would be predicted), despite more PPAR being present and located on 
PPAR response elements in the promoter of PPAR-transcribed genes (Fan et al., 2011; 
Flores et al., 2011). Overall, our understanding of post-translational regulation of the PPAR 
complex itself remains limited and should be expected to be complex and unpredictable, but 
nonetheless critical to our understanding of PPARs in metabolism and the pathophysiology 
of disease.
5. Conclusions
Muscle ring finger-1 (MuRF1) is the first muscle-specific ubiq-uitin ligase reported that 
directs nuclear PPARα inhibition in a proteasome-independent manner. These studies 
demonstrated that increasing MuRF1 inhibits fatty acid oxidation, while enhancing glucose 
oxidation and inhibiting PPARα. Mechanistically, these studies report that cardiomyocyte 
MuRF1 inhibits PPARα activity by a novel mechanism by which the cardiomyocyte nuclear 
receptor PPARα is mono-ubiquitinated (adjacent to a novel NES also identified in these 
studies) and subsequently removes it from the nucleus by the cells nuclear export 
machinery. Furthermore, the present study identified the first confirmed NES in PPARα, 
along with three specific lysines (292, 310, 388) required for MuRF1s targeting of nuclear 
export. These studies identify the role of ubiquitination in regulating cardiac PPARα in vivo, 
including the cardiac-specific ubiquitin ligase that may be responsible for this critical 
regulation of cardiac metabolism in heart failure.
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Increasing MuRF1 expression enhances primary cardiomyocyte glucose oxidation and 
inhibits fatty acid (oleate) oxidation. A. 14C-Glucose and B. 14C-Oleate oxidation in 
neonatal rat cardiomyocytes (NRCMs) with increasing MOI of Ad.GFP or Ad.Myc-MuRF1. 
Etomoxir, a commercially available fatty acid oxidation inhibitor was used as a control to 
demonstrate that fatty acid oxidation inhibition could be detected. C. Using the glucose and 
fatty acid (oleate) oxidation determination, shifts in calculated ATP resulted in no net 
change of ATP (based on 14CO2 released from the cells, assuming 1 mol glucose =38 ATP; 
1 mol oleate =129 ATP). Data represent 3 independent experiments run in triplicate. D. 
Immunofluorescence microscopy detection of GFP (from Ad.GFP or Ad.MuRF1) vs. non-
infected cells run in parallel with 14C-Glucose/14C-Oleate replicates. A One-Way ANOVA 
was used to determine significance. #p < 0.05 vs. media alone. *p < 0.05 vs. Ad.GFP; **p < 
0.05 vs. untreated control cells.
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MuRF1 regulation of PPARα, PPARβ/δ, and PPARγ activity in vitro. PPARα, PPARβ/δ, 
and PPARγ activity was determined using PPRE-driven luciferase plasmids, co-transfected 
with a PPARα, PPARβ/δ, and PPARγ expression plasmid, in the presence or absence of 
MuRF1. A. In Cos7 cells, MuRF1 significantly inhibited PPARα, but not B. PPARβ/δ, or C. 
P PPARγ activity. Similarly, MuRF1 significantly inhibited D. PPARα, but not E. PPARβ/δ, 
or F. PPARγ activity in cardiac-derived HL-1 cardiomyocyte cell line. G. Determination of 
nuclear PPARα binding to PPRE DNA using a capture ELISA platform demonstrates the 
increasing MuRF1 expression results in decreased nuclear PPARα activity; conversely H. 
decreasing MuRF1 expression with siRNA results in increased nuclear PPARα activity in 
HL-1 cardiomyocytes. I. Quantitative RT-PCR analysis reported cardiac PPARα-activated 
mRNA expression in HL-1 cardiomyocytes with increased MuRF1 (transduced with 
Ad.GFP-Myc-MuRF1) or J. decreased MuRF1 expression (Ad.GFP-shMuRF1). Expression 
of cells without treatment was set at 1. Data are mean ± SEM from at least 3 independent 
experiments. *p < 0.05; **p < 0.01; ***p < 0.001 vs. Ad.GFP or Ad.scMuRF1 infected 
control cells.
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Cardiomyocyte MuRF1 expression regulates PPARα, PPARβ/δ, and PPARγ activity in vivo 
without altering protein levels of PPARα. A. The increased cardiomyocyte MuRF1 in 
MuRF1 Tg+ hearts results in decreased nuclear PPARα binding activity, but not PPARβ/δ, 
or PPARγ activity for binding PPRE DNA using a capture ELISA platform. B. Conversely, 
MuRF1−/− hearts lacking cardiomyocyte MuRF1 have a >5 fold increase in nuclear PPARα 
binding activity, but no effect on PPARβ/δ, or PPARγ activity using a capture ELISA assay. 
C–F. Quantitative metabolomics analysis of acyl-carnitine (AC) in MuRF1 Tg+ and 
MuRF1−/− hearts. Normalized concentrations of C. total acylcarnitines (Total AC). Further 
breakdown to these total ACs by D. long chain (C14–C22), E. medium chain (C6–C12), and 
F. short chain (C2–C5), illustrates MuRF1's regulation of fatty acid oxidation significantly 
affects long and short chain ACs, while medium ACs are not affected. Subcategories of 
acylcarnitines classified by chain length measured in mouse heart homogenates from the 
indicated strain and represented by box and whiskers plotting the median and min to max, 
respectively (n =3–4 biological replicates per strain). G. Western immunoblot analysis 
MuRF1 Tg+ (N =4/group) and MuRF1−/− (N =3/group) hearts have PPARα, PPARβ/δ, and 
PPARγ expression that do not differ from strain-matched control hearts (N =4 and N =3, 
respectively), with the exception of PPARβ which was decreased in MuRF1−/− hearts. H. 
qPCR analysis of reported cardiac PPARα-regulated mRNA illustrates that the increased 
MuRF1 in MuRF1 Tg+ hearts increases the expression of ACC1 and ACO1 while I. 
MuRF1−/− hearts have increased levels of all ACC1, ACO1, LCAD, and MCAD. Data are 
mean ± SEM. A Student's t-test was performed to determine significance between groups 
(Panels A, B, G, H, *p < 0.05, **p < 0.01, ***p < 0.001). Changes in total, long chain, and 
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short chain were significant at an FDR <5% (*) (Panels C–F, post-tests: *p < 0.001 
comparing MuRF1+/+ versus MuRF1−/−, and Wild-typeMuRF1Tg vs. MuRF1 Tg+, 
respectively. **p < 0.01 and ***p < 0.001 MuRF1−/− vs. MuRF1 Tg+). n.s. =not 
significant.
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MuRF1 interacts with PPARα by co-immunoprecipitation and increasing MuRF1 
expression removes nuclear localization. A. Immunoprecipitation of MuRF1 in HL-1 cells 
(forward reaction), followed by immunoblot analysis of endogenous PPARα detected a 
specific interaction between MuRF1 and PPARα. B. Immunoprecipitation of endogenous 
PPARα in HL-1 cells (reverse reaction) also detected a specific interaction between PPARα 
and MuRF1. C. Confocal microscopy analysis of HL-1 cells revealed that at the single cell 
level, increasing MuRF1 expression (Ad.MuRF1 25 MOI) caused endogenous PPARα to 
move out of the nucleus (middle panel) compared with controls (top). D. The removal of 
endogenous PPARα by MuRF1 (25 MOI) was found in most of the cells compared with 
controls, which rarely lacked nuclear endogenous PPARα. E. Analysis of at least 3 
independent experiments from >5 fields of view demonstrated that increasing MuRF1 
(AdMuRF1) decreased the nuclear endogenous PPARα 70% (99.2%–29.2%), while 
increasing the number of cells with cytoplasmic endogenous PPARα 70% (70.8%–0.8%). N 
=244 (Ad.GFP), N =228 (Ad.myc-MuRF1). A Student's t-test was performed to determine 
significance between groups. *p < 0.01.
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MuRF1's nuclear removal and inhibition of PPARα activity is dependent on the nuclear 
export machinery. A. The MuRF1-mediated removal of endogenous PPARα, found in cells 
with increased MuRF1 (Ad.myc-MuRF1 vs. Ad.GFP, top two rows) B. is inhibited when 
cells are treated with Leptomycin B (LMB), an inhibitor of exportin (CRM1)-mediated 
nuclear export. By recognizing leucine-rich nuclear export signals (NESs) in target proteins 
like PPARα, CRM1 mediates the nuclear export and inhibition. C. In parallel experiments 
measuring nuclear PPARα activity (ability of isolated nuclear PPARα to bind PPRE-coated 
ELISA plates), increasing MuRF1 inhibited PPARα activity ~60% compared with controls. 
D. Paralleling MuRF1's removal of nuclear PPARα in confocal microscopy experiments, 
LBM inhibition of nuclear export in HL-1 cells prevented MuRF1's inhibition of PPARα 
activity. E. The presence of MuRF1 is rarely found in the nucleus in normal conditions (e.g. 
Fig. 4). However, in the presence of LMB, MuRF1 was found in greater than 25% of HL-1 
cells 4 h after treatment indicating that MuRF1 movement in and out of the nucleus is 
dependent upon nuclear export of it or other interacting proteins necessary for MuRF1 to 
interact with nuclear receptors. A Student's t-test was performed to determine significance 
between Ad.GFP and Ad.MuRF1. *p < 0.05. n.s. =not significant.
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MuRF1 binds PPARα through its MFC domain and promotes PPARα monoubiquitination 
through its ubiquitin ligase activity. A. Immunoprecipitation of PPARα (anti-FLAG) in cells 
co-transfected FLAG-PPARα and myc-MuRF1 deletion mutants identified that MuRF1's 
MFC (MuRF Family Conserved) region is required for its interaction with PPARα. B. 
Western immunoblot analysis of in vitro ubiquitination reactions containing recombinant 
E1, E2, MuRF1, PPARα, and ubiquitin (= Full reaction) demonstrates that MuRF1 mon-
oubiquitinates PPARα in a specific manner (compare to No E1, No E2, No MuRF1, No 
PPARα, No ubiquitin lanes). C. Determination of MuRF1's ubiquitination pattern in vivo 
similarly reveals the presence of monoubiquitination. Specifically, HL-1 cells transfected 
with FLAG-PPARα and HA-Ubiquitin (HA-Ub) with increased MuRF1 (Ad.Myc-MuRF1 
vs. Ad.GFP, 4 h) demonstrates that PPARα is multi-monoubiquitinated. D. Similarly, 
PPARα is multi-monoubiquitinated in HEK293 cells in a RING finger-dependent manner. 
Compared to MuRF1's monoubiquitination of PPARα, MuRF1ΔRING (MuRF1 lacking the 
N-terminal RING finger domain with ubiquitin ligase activity) is unable to similarly 
monoubiquitinate PPARα despite equal expression levels of MuRF1 (IB: MuRF1 [cMyC]).
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Identification and confirmation of PPARα's first nuclear export sequence targeting nuclear 
export. Three PPARα constructs were made to confirm if putative NESs identified here 
(strategy outlined in Fig. A.3A, in blue): 1) a FLAG-tagged wild-type PPARα; 2) a full 
length FLAG-tagged NES1 mutant PPARα, whereby all 4 leucines in the NES1 region were 
replaced with alanine; and 3) a full length FLAG-tagged NES2 mutant PPARα, with all 3 
leucines in the NES2 region were replaced with alanine. A. Compared to wild-type PPARα 
(top row), NES1, but not NES2 transfected cardiomyocytes, have increased nuclear staining 
consistent with an impaired nuclear export. B. To determine if the enhanced nuclear 
concentration of the NES1 mutant PPARα impaired MuRF1's ability to remove it, parallel 
studies with increased MuRF1 were performed to test MuRF1's ability to remove PPARα 
from the nucleus. Increasing MuRF1 (Ad.myc-MuRF1 25 MOI) reduced nuclear NES1 
mutant PPARα compared with control (Ad.GFP 25 MOI) by 63.2% (83.9%–20.7%), 
consistent with the 70% reduction seen in endogenous PPARα in previous experiments (Fig. 
5). Despite the importance of the NES1 for nuclear export, modification of MuRF1's 
modification and nuclear export of this mutant PPARα is unaffected.
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Three specific lysines surround NES1 are required for MuRF1's nuclear export of PPARα. 
Since ubiquitin ligases, including MuRF1, place ubiquitin on protein lysines, we next 
determined the lysines required for MuRF1's nuclear export of PPARα. Six additional 
FLAG-tagged PPARα constructs were created with the six most proximal lysines to the 
NES1 and NES2 mutated to arginine, preventing ubiquitination from occurring (see Fig. A.3 
for details). Compared to controls (row 1), MuRF1 clears wild-type PPARα in HL-1 
cardiomyocytes (row 2). However, full length PPARα with a single lysine to arginine 
mutation at surrounding NES1 (A1, A2, and A3) is not cleared from the nucleus. With 
increased MuRF1 (Ad.MuRF1), PPARα mutants A1, A2, and A3 localize in the nucleus 
(rows 3–5, right table – 89.4%, 77.4%, and 78.3%, respectively) to the same extent as 
Ad.GFP controls (row 1, 81.1%). In contrast, increased MuRF1 (Ad.MuRF1) results in 
nuclear removal of wild-type PPARα, remaining in only 26.4% of the cells (row). PPARα 
mutants A4, A5 and A6 were localized only in cytoplasm as PPARα control (Fig. A.4), 
indicating that the lysines A4, A5, A6 are not potential ubiquitination sites needed for 
MuRF1's nuclear export of PPARα.
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